Author:
Paes Marcela F,Daltoé Renata D,Madeira Klesia P,Rezende Lucas CD,Sirtoli Gabriela M,Herlinger Alice L,Souza Leticia S,Coitinho Luciana B,Silva Débora,Cerri Murilo F,Chiaradia Ana Cristina N,Carvalho Alex A,Silva Ian V,Rangel Leticia BA
Abstract
Abstract
Background
Ovarian cancer is sixth most common cancer among women and the leading cause of death in women with gynecological malignancies. Despite the great impact ovarian cancer has on women's health and its great impact in public economy, Brazil still lacks valuable information concerning epidemiological aspects of this disease
Methods
We've compiled clinical data of all ovarian tumors registered at the two public hospitals of reference (1997 - 2007), such as: patients' age at diagnosis, tumor histological type, tumor stage, chemotherapy regimens, chemotherapy responsiveness, disease-free survival, and overall survival.
Results
Women's mean age at diagnosis was 54.67 ± 13.84 for ovarian cancer, 46.15 ± 11.15 for borderline tumors, and 42.01 ± 15.06 for adenomas. Among epithelial ovarian cancer cases, 30.1% were of serous, 13.7% were of mucinous, and 13.7% were of endometrioid type; exceptionally serous carcinoma was diagnosed in women younger than 30 years old. Endometrioid cancer had lower disease-free survival than others (p < 0.05). Cases were predominantly diagnosed as poor prognosis disease (FIGO III and IV, 56.2%). Regarding responsiveness to platinum-based therapy, 17.1% of patients were resistant, whereas 24.6%, susceptible. From these, we found equally responsiveness to platinum alone or its association with paclitaxel or cyclophosphamide.
Discussion
Our data agreed with other studies regarding mean patients' age at diagnosis, histological type frequency, FIGO stages distribution, and chemotherapy regimens. However, the histological type distribution, with equal contribution of mucinous and endometrioid types seems to be a unique characteristic of the studied highly miscegenated population.
Conclusion
We have enlighten the profile of the studied ovarian cancer population, which might enable the development of more efficient political strategies to control this malignancy that is the fifth leading cause of cancer-related deaths among women.
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Oncology
Reference38 articles.
1. American Cancer Society. Cancer Facts and Figures 2011
[http://www.cancer.org/Cancer/OvarianCancer/DetailedGuide/ovarian-cancer-key-statistics]
2. Jacobs IJ, Menon U: Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3: 355–66. 10.1074/mcp.R400006-MCP200
3. Tchabo NE, Liel MS, Kohin EC: Applying proteomics in clinical trials:Assessing the potential and practical limitation in ovarian cancer. Am J Pharmacogenomics 2005, 5: 141–8. 10.2165/00129785-200505030-00001
4. Willmott LJ, Fruehauf JP: Targeted therapy in ovarian cancer. J Oncol 2010, 9. Article ID 740472
5. Janssen-Heijnen ML, Houterman S, Lemmens VE, Louwman MW, Maas HA, Coebergh JW: Prognostic impact of increasingage and co-morbity in cancer patients: A population-base approach. Crit Rev Oncol Hematol 2005, 55: 231–40. 10.1016/j.critrevonc.2005.04.008
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献